Ding! Please sign for your Christmas Eve gift!
Release Date:
2022-12-21 11:38
Quality First, Innovation-Based
Quality First, Innovation Based

With the adjustment of epidemic prevention and control measures, Shanghai has entered a new phase in its fight against the virus. On this invisible battlefield, each of us—striving to live well and working diligently—is a warrior. We are deeply grateful to every colleague who remains steadfast at their post or stays home, tirelessly battling the virus while continuing to do their job. You are all truly outstanding.
In the midst of the pandemic, people have come to appreciate the true significance of health and recognize the profound impact and transformative power that successful drug development can have on humanity. Hycells Biotechnology has wholeheartedly responded to epidemic prevention and control policies, placed great emphasis on the well-being and healthy lifestyles of its employees, and worked diligently to maintain normal business operations and deliver on time as promised to our customers.
In the Hycells Biotechnology R&D Laboratory, a dedicated team of colleagues remains fully committed to ensuring the orderly and stable progress of client service projects, thereby maximizing on-time delivery of Hycells’s services for clients’ subsequent R&D experiments. Quality first, innovation at our core—this is the promise we steadfastly uphold for our clients.
The Human Resources and Administration Department at Hycells has also thoughtfully prepared防疫 (epidemic-prevention) gift packs for everyone, hoping to bring a touch of warmth and our sincerest wishes before the arrival of Christmas Eve this cold winter.
Wishing each of us in advance All are safe and sound. , Let’s welcome the arrival of the New Year together. Ding! Christmas Eve Gift Please sign for it!
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.